Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ACELYRIN Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
General
Participant has provided signed informed consent including consenting to comply with the requirements and restrictions listed in the informed consent form (ICF) and in protocol
18 years of age or older
No known history of active tuberculosis unless adequately treated according to World Health Organization/Center for Disease Control and Prevention therapeutic guidance and determined to be fully recovered by a tuberculosis specialist
Type of Participant and Disease Characteristics
Diagnosis of HS for ≥ 6 months prior to first dose of study drug
Hidradenitis suppurativa lesions present in ≥ 2 distinct anatomic areas, one of which is Hurley Stage II or Hurley Stage III
A total AN count of ≥ 5 at screening and Day 1 prior to enrollment/randomization
Participant must have had an inadequate response to oral antibiotics OR exhibited recurrence after discontinuation to, OR demonstrated intolerance to, OR have a contraindication to oral antibiotics for treatment of their HS
Must agree to use daily or a minimum of 3 days a week over-the-counter topical antiseptics
Participant must be willing to complete a daily skin pain diary
You may not be if
Medical Conditions
Draining fistula count of \> 20
Outpatient surgery ≤ 8 weeks prior or inpatient surgery ≤ 12 weeks prior to enrollment/randomization
Other active skin disease or condition that could interfere with study assessments
History of active inflammatory bowel disease (IBD) OR symptoms within the last year that may be suggestive of IBD
Chronic pain not associated with HS
Uncontrolled, clinically significant system disease
History of demyelinating disease or neurological symptoms suggestive of demyelinating disease
Malignancy within 5 years
The participant is at risk of self-harm or harm to others
Active infection or history of certain infections
Tuberculosis or fungal infection seen on available chest x-ray taken within 3 months prior to first dose of study drug or at screening (Exception: documented evidence of completed treatment and clinically resolved)
Known history of human immunodeficiency virus (HIV)
